OZEMPIC® 0.25 mg (International English)
OZEMPIC® 0.25 mg is a once-weekly injectable semaglutide treatment used to improve blood glucose control in adults with type 2 diabetes, alongside diet and exercise. The 0.25 mg dose is the starter dose, intended to help patients adjust to therapy before increasing to higher therapeutic strengths. OZEMPIC® is also commonly used off-label in some regions for weight management under medical supervision due to its appetite-regulating effects.

Key Benefits
• Starter dose designed to help patients acclimate before progression to higher doses
• Helps lower blood sugar levels in adults with type 2 diabetes
• Supports weight reduction by reducing appetite and calorie intake
• Once-weekly injection for convenient dosing
• Can be used alone or with other diabetes medications, as advised by a clinician

How It Works
OZEMPIC® contains semaglutide, a GLP-1 receptor agonist that mimics the body’s natural incretin hormone. It works by increasing insulin secretion when blood sugar is elevated, reducing glucagon release, slowing gastric emptying, and reducing appetite. Together, these actions help improve glucose control and support weight management.

Ideal Candidates
• Adults with type 2 diabetes requiring improved blood sugar control
• Individuals needing a starter dosage prior to dose escalation
• Patients with overweight or obesity using the medication under physician guidance
• Those seeking a once-weekly, easy-to-use injectable treatment

Administration
Delivered via a prefilled injection pen, administered subcutaneously once weekly in the abdomen, thigh, or upper arm.
The 0.25 mg dose is not intended for long-term maintenance, but rather for the first several weeks of therapy before increasing to 0.5 mg or higher, as directed by a healthcare professional.

Possible Side Effects
Common temporary side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, or decreased appetite. These are usually mild and tend to improve as the body adjusts.
Less common but more serious risks include pancreatitis, gallbladder issues, or allergic reactions. Patients should be monitored by a licensed healthcare provider during treatment.